A new clue in autism genetics—not a simple explanation.

What did researchers examine?

In a paper published October 9, 2026, researchers at Baylor College of Medicine and collaborating institutions studied regulatory DNA sequences that help control the X-chromosome gene MECP2. The team tested rare variants using molecular assays and laboratory-grown human neurons, and interpreted the findings alongside prior mouse research.

Two noncoding variants identified in autistic males altered regulatory activity. In one tested case, a promoter variant reduced MECP2 expression by about 30% in human neurons. The team reported that the variant had been inherited from an unaffected mother and was found in an individual diagnosed with autism and ADHD. These observations suggest one possible biological pathway in some presentations—not a general explanation of differences in autism diagnosis rates.

Important limitations

Much of the evidence relies on specific rare genetic variants, experiments in cells, and comparisons with mouse models. These cannot determine a person's neurodevelopmental trajectory or the cause of autism in a broader population. Diagnosis frequency reflects several factors—including detection and referral—and no single gene explains the overall pattern.

Most families do not need a new MECP2 test because of this headline. Questions about whether clinical genetic evaluation is appropriate should be considered with the person's treating clinician or a genetic counselor, using existing standards and the individual's circumstances.

What NeuroCoach will follow next

Independent replication, population-level studies, understanding of noncoding variants beyond MECP2, and evidence showing whether genetic interpretation changes care. Until then, support should remain guided by the person's communication, learning, daily-life needs, preferences, and goals.